Madhuri R. Hegde, Ph.D.
`
`
`
`
`
`
`
`Name:
`
`Office Address:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CURRICULUM VITAE
`
`
`
`
`Madhuri R. Hegde
`
`
`
`
`
`
`
`Department of Human Genetics
`615 Michael Street
`Whitehead Building, Suite 301
`Atlanta, Georgia 30322
`Telephone: 404-727-3863
`Fax: 404-727-3949
`
`mhegde@emory.edu
`
`Page 1
`
`
`
`
`
`
`
`
`E-mail Address:
`
`Citizenship:
`
`
`Current Titles and Affiliations:
`
`
`Academic Appointment: Professor
` Department of Human Genetics
` Emory University School of Medicine
` August 2013 to present
` Professor
` Department of Pediatrics (secondary appointment)
` Emory University School of Medicine
` November 2013 to present
`
` Adjunct Associate Professor
` The University of Texas M.D. Anderson Cancer Center
` School of Health Sciences, Houston, TX
` August 2004 to present
`
`Clinical Appointment: Executive Director, Emory Genetics Laboratory
`
`
` Emory University School of Medicine
`
` Department of Human Genetics, Division of Medical Genetics
` Emory Genetics Laboratory
`
`
` December 2012 to present
`
`
`Previous Academic and Professional Appointments:
`
`1992 – 1995
`
`
`
`1995 – 1996
`
`
`
`
`1996- 2000
`
`
`
`2000– 2003
`
`
`
`New Zealand (Permanent Resident: United States; Eligible for Citizenship, 2007)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Senior Research Fellow
`Bombay Hospital, University of Bombay, Bombay, India
`
`Research Associate
`DNA Diagnostic Laboratory, Auckland Hospital, Auckland, New Zealand
`
`Scientific Officer
`DNA Diagnostic Laboratory, Auckland Hospital, Auckland, New Zealand
`
`Postdoctoral Fellow
`Department of Human Genetics, Baylor College of Medicine, Houston, TX
`
`
`2003-2006
`
`
`
`2006-2009
`
`
`
`
`Assistant Professor
`Department of Human Genetics, Baylor College of Medicine, Houston, TX
`
`Assistant Professor
`Department of Human Genetics, Emory University School of Medicine, Atlanta, GA
`
`
`GeneDX 1003, pg. 1
`
`

`

`Madhuri R. Hegde, Ph.D.
`
`
`
` Page 2
`
`
`
`
`
`
`
`
`
`
`Associate Professor
`Department of Human Genetics, Emory University School of Medicine, Atlanta, GA
`
`Professor
`Department of Human Genetics, Emory University School of Medicine, Atlanta, GA
`
`2009-2013
`
`
`
`2013-
`
`
`
`Previous Administrative and/or Clinical Appointments:
`
`1996- 2000 Scientific Director, DNA Diagnostic Laboratory,
` Auckland Hospital, Auckland, New Zealand
`
` Assistant Laboratory Director, DNA Diagnostic Laboratory
`2001 – 2006
` Department of Human Genetics, Baylor College of Medicine, Houston, TX
`
` Co- Director, DNA Diagnostic Laboratory
`2006 – 2006
` Department of Human Genetics, Baylor College of Medicine, Houston, TX
`
`2006-2010
`
`Senior Laboratory Director, Emory Genetics Laboratory, Atlanta, GA
`
` Scientific Director, Emory Genetics Laboratory, Atlanta, GA
`
`
`
`
`
` Clinical Molecular Geneticist, American Board of Medical Genetics (renewed 2013)
`
`
`
`
`
`
`
`
`
` B.S., Microbiology/Genetics, University of Bombay, Bombay, India
`
`2010-2012
`
`
`
`
`Licensures/Specialty Boards:
`
`2005
`
`
`Education:
`
`1987
`
` M.Sc., Microbiology/Genetics, University of Bombay, Bombay, India, Advisor: Prof. M.Y.
`1992
`Kamat, Professor and Head, Department of Food Science and Technology, University Institute of Chemical
`Technology (UICT), University of Bombay, India
`
`2000 Ph.D., Applied Science, University of Auckland, School of Biological Sciences, Auckland, New
`Zealand, Advisor: Prof. Richard Bellamy, Dean, Faculty of Science, The University of Auckland
`
`
`Postdoctoral Training:
`
`2000-2003
`
`
`
`
`
`Committee Memberships:
`
`National and International:
`
`
`
`
`AMP Economic Affairs Committee: NGS Pricing Project Oversight Committee (NPP)
`
`Chair- Colorectal Cancer Laboratory Guidelines Committee
`
`Next Generation Sequencing Guidelines committee
`
`Sequence Interpretation Guidelines committee
`
`American College of Medical Genetics: CAP Liaison (Molecular)
`
`American College of Medical Genetics Representative to NIH R25 grant to ASCP
`
`
`
`
`
` Department of Human Genetics, Baylor College of Medicine
` Mentor: Carolyn Sue Richards, Ph.D.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` 2014-
`
` 2008-
`
` 2011-
`
` 2006-
`
` 2013-
`
`GeneDX 1003, pg. 2
`
`

`

`Madhuri R. Hegde, Ph.D.
`
`
`
` Page 3
`
`“Training Residents in Genomics (TRIG)”
`
`
`
`
`
`ACMG Task Force on Whole Genome Sequencing
`
`
`
`
`
`
`
`
`
`
`CDC- Get RM Expert Panel member 2007-
`
`
`
`
`College of American Pathologists (CAP) Next gen sequencing guidelines committee
`
`CLSI- Document Development Committee on Microarrays for Cytogenetics and Oncology (MM21) 2011-
`
`AMP 2012- 2013 Program Committee
`
`Association of Molecular Pathology, Training and Education Committee
`
`Scientific Advisory Board- Microarray based assays 2008- 2011
`Neuromuscular diseases- European Union
`
`American College of Medical Genetics, Quality Assurance Committee
`
`
`Regional and State:
`
`Texas Cancer Genetics Network, Houston, TX 2003-2005
`
`
`
`
`
`Institutional:
`
`
`
`
`
`
`
`Scientific Advisory Board, Molecular Genetic Technology Committee-
`M.D. Anderson Cancer Center, School of Health Sciences, Houston, TX
`
`ACMG Postdoctoral Training Program Committee
`Division of Medical Genetics, Emory University
`
`Clinical Services Utilization Subcommittee
`Emory Medical Laboratories
`
`Clinical Services Laboratory Subcommittee
`Baylor College of Medicine, Houston, TX
`
`
`
`Advisor
`
`
`Parent Project Muscular Dystrophy: Duchenne Connect, Registry
`
`
`
`
`Cure CMD: Congenital Muscular Dystrophy Registry
`
`Principal Investigator : MutaDataBase (Mutation database) 2010-
`
`Jain Foundation Dysferlin Project- India
`
`CDC- Next Gen Sequencing Expert meeting
`
`
`Founder
`
`
`Organization of Rare Disorders (ORD), India
`
`
`Consultancy
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` 2013-
`
`
`
` 2011-
`
` 2011-
`
`
`
` 2011-2013
`
` 2006- 2009
`
` 2006-2011
`
` 2005-
`
` 2006 –
`
` 2008–
`
` 2003– 2006
`
` 2008-
`
`
`
` 2009-
`
` 2010-
`
` 2011-
`
`
`
`
`
` 2013-
`
`
`
`
`
`
`
`
`
`GeneDX 1003, pg. 3
`
`

`

`Madhuri R. Hegde, Ph.D.
`
`
`
` Page 4
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` 2014-
`
` 2013-
`
` 2012-
`
` 2011-
`
` 2011-2014
`
` 2013-
`
` 2013
` 2013
` 2013-
` 2013
` 2012-
` 2012
` 2012
` 2010-2013
` 2011
` 2011
` 2010
` 2010
`
`
`
`
`
`
`
`
`Phoenix Children’s Hospital
`
`Ingenuity systems (Qiagen)
`
`Tessarae
`
`Oxford Gene Technologies
`
`RainDance Technologies
`
`
`
`Scientific Expert
`
`Myriad VS GeneDx
`
`
`Grant Review:
`
`
`
`
`
`
`Belgium Research Council
`
`
`
`
`
`Canada Cancer Organization
`
`
`
`
`
`Telethon
`
`
`
`
`
`
`
`Duchenne Fund, Italy
`
`
`
`NHGRI- Genomic Medicine Pilot Demonstration Projects
`
`Congressionally Directed Medical Research Program (CDMRP)
`
`Wellcome Trust, UK
`
`
`
`
`
`NIH (ZRG1 IMST-J (15) Genes, Genomes, and Genetics, SBIR/STTR review)
`National Medical Research Council, Singapore
`
`
`
`Princess Beatrix Research Fund, Netherlands
`
`
`
`Medical Research Council, Australia
`
`
`
`
`Medical Research Council, New Zealand
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Editor:
`
`Communicating editor- Human Mutation
`
`
`Manuscript Reviewer:
`
`American Journal of Human Genetics (2011- present)
`American Journal of Medical Genetics (2009; 2010)
`American Journal of Pathology (2011)
`Cancer Detection and Prevention (2011)
`Clinical Genetics (2009; 2011; 2012)
`European Journal of Human Genetics (2011;2012)
`Genetics in Medicine (2006- present)
`Human Mutation (2005- present)
`Human Molecular Genetics (2009, 2011)
`Journal of Clinical bioinformatics (2013)
`Journal of Medical Genetics (2010; 2011)
`Journal of Molecular Diagnostics (2006-present)
`Journal of Pediatrics (2012)
`Journal of Rare and Orphan Diseases (2012)
`Microarrays (2013)
`Nature Reviews Genetics (2012)
`Neuropsychiatry and Neurogenetics (2011)
`Neurogenetics (2011)
`Neuromuscular disorders (2011; 2012)
`Orphanet Journal of Rare Diseases (2011; 2012)
`PLoS Genetics (2011;2012)
`
`GeneDX 1003, pg. 4
`
`

`

`Madhuri R. Hegde, Ph.D.
`
`
`
` Page 5
`
`PLoS One (2011; 2012; 2013-)
`Prenatal Diagnosis (2011)
`BMC Genetics (2011; 2012)
`
`
`
`
`Honors and Awards:
`
`G.D. Gokhale Trust Fund Fellowship for MSc 1988
`
`Recipient of the Best article, Bombay Technologist (1991) 1992
`Publication of University Institute of Chemical Technology, Mumbai, India
`
`Graduate Aptitude Test GATE/University Grant Commission (National Level) 1993
` Scholarship for Ph.D
`
`Bronlund Trust Fund Award for Auckland Healthcare employees 1996
`Auckland Hospital, Auckland, New Zealand
`
`University of Auckland Research Fund Award 1998
`
`M.D. Anderson Cancer Center, Outstanding Faculty Award 2005
`
`ACMGGF –Signature Genomics Laboratories Award 2008
`
`Faculty recognition “Phi Beta Kappa”, Emory College
`
`
`
`Society Memberships:
`
`
`American Society of Human Genetics
`
`American College of Medical Genetics, Fellow
`
`Association for Molecular Pathology 2005-
`
`Baylor College of Medicine, Cancer Center 2005- 2006
`
`Human Genetics Society of Australasia 1998-
`
`Winship Cancer Institute, Emory University 2007-
`
`
`Leadership Positions:
`
`American College of Medical Genetics, Chair, Colorectal Cancer Laboratory Guidelines
`
`
`
`American College of Medical Genetics, Course Director and Faculty
`Short Course on Next Generation Sequencing in Clinical Practice (2012)
`
`Association of Molecular Pathology, Leader, Trainee Exchange Program 2006-2009
`
`Association of Molecular Pathology, Chair (Chair-Elect- 2010): Genetics Subdivision 2011-
`
`
`
`Association of Molecular Pathology, Board of Directors
`
`Nominated to American Board of Medical Genetics (ABMG), Board of Directors
`
`Nominated to American College of Medical Genetics (ACMG), Board of Directors
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` 2011
`
` 1995 –
`
` 2005–
`
`
`
`
`
`
`
`
`
`
`
` 2006-
`
` 2011-
`
` 2011-
`
` 2012
`
`
`
` 2012
`
`GeneDX 1003, pg. 5
`
`

`

`Madhuri R. Hegde, Ph.D.
`
`
`
` Page 6
`
`
`
` 2013
`
`Co-Chair, Organizing Committee, International conference on Genetics and Genomics
`New Delhi, India
`
`
`
`
`
`Research Focus:
`
`Muscular Dystrophy: Understanding the functional intricacy and the effect of mutation on the protein expression is
`critical to making the right choice of therapeutic approach for Congenital Muscular Dystrophy (CMD) and Limb Girdle
`Muscular Dystrophy (LGMD). We are using an integrated approach using next generation genotyping, sequencing
`and microarray tools, to identify new gene and create a comprehensive map of the CMD and LGMD muscle exome,
`transcriptome and proteome, which may aid in choosing the most appropriate and focused personalized therapeutic
`approach.
`
`Newborn screening: Duchenne muscular dystrophy (DMD) is an inherited form of muscular dystrophy which occurs in
`about 1 out of every 3,600 male infants. In spite of the high frequency of disease, newborn screening (NBS) for DMD
`is not in practice except in a few countries worldwide. Though, creatine kinase (CK) level testing has been attempted
`as a NBS method, the high false positive rate and the need for follow-up re-testing have rendered the test
`unacceptable for NBS. Based on the promising reports from a recent study that introduced a two-tier screening
`system using dried blood spots from birthing process, we are validating and implementing a comprehensive and low
`cost next generation sequencing (NGS) approach to detect all types (deletions, duplications and point mutations) in
`the DMD gene.
`
`Dysferlinopathies: DYSF is a large gene comprising 55 exons and spanning a genomic region of >150 kb. Although
`mutation detection provides the most definitive diagnosis, it does not provide information about protein expression.
`We are using a modified monocyte assay method to identify dysferlin deficient patients and compare the dysferlin
`expression data with the genotype data to define the correlation of protein expression and disease severity. This data
`will useful in monitoring patients entering gene therapy trials for dysferlin. We have also implemented this strategy in
`India.
`
`Clinical Focus:
`
`I devote a significant portion of my time to directing Emory Genetics Laboratory (EGL) within the Division of
`
`Medical Genetics in the role of Executive Director. I have the responsibility for the overall operation and management
`of EGL as well as setting strategic goals to maintain EGL as one the nation’s leading academic genetic testing
`laboratories. Besides overseeing the administrative sections of EGL, I also oversee development and transition of
`new state of the art tests into clinical practice. The focus of my clinical research and development is to develop and
`perform comprehensive mutation analysis and interpretation for complex or challenging genetic disorders using
`multiple approaches. The primary focus of my clinical work is the development of high-throughput assays for rare
`disorders using next generation sequencing and microarrays for panels, exome and genomes. I also direct the
`bioinformatics efforts for variant interpretation and automation for streamlining testing pipelines.
`
`Clinical Sequence Variant Classification and EMR integration: Current technology allows clinical laboratories to
`rapidly translate research discoveries from small patient cohorts into clinical genetic tests; therefore, a potentially
`large proportion of sequence variants identified in individuals with clinical features of a genetic disorder remain
`unpublished. Clinical laboratories willing to share this data face technological and practical barriers perpetuating a
`current problem: inconsistent interpretation of sequence variants from clinical laboratories working with different
`information. We have developed an in-house data management system, which is a highly-curated clinical grade
`variant database with a data structure designed to facilitate sharing of variants identified at EGL. This system also
`tracks changes in variant classifications, generating notifications for the laboratory about which cases are in need of a
`review and possible report update. The second component, EmVClass, is a web-based tool that allows any user to
`view and request a review of variants classified at EGL. These software tools provide a solution to two pressing
`problems in clinical genetic testing: how to make sequence variants identified in a clinical laboratory freely available
`to the community and how to communicate changes in variant classification to healthcare providers.
`
`Medical Exome: Next generation sequencing (NGS) technologies are increasingly gaining acceptance in clinical
`laboratories in the form of targeted gene panels and exome sequencing. These targeted tests are used extensively in
`the testing for Mendelian diseases with locus and allelic heterogeneity and cancer. While their moderate size allows
`for high coverage, technical sensitivity and the ability to generate data for every interrogated base, their clinical
`sensitivity is usually suboptimal. In contrast, exome sequencing offers enhanced detection rates but does not return
`
`GeneDX 1003, pg. 6
`
`

`

`Madhuri R. Hegde, Ph.D.
`
`
`
` Page 7
`
`data for the entire target region, thereby limiting its clinical utility. To address these challenges, in collaboration with
`Dr. Birgit Funke (Harvard) and Dr. Avni Santani (CHOP) we are performing an in-depth and iterative curation of all
`genes that are currently known to be medically relevant. We are also developing a clinically validated enhanced
`exome assay where coverage of medically relevant genes is optimized. The assay design will be shared with the
`genetic testing community to promote standardization of medical sequencing. This information will be critical for
`clinical laboratories, physicians, and researchers that interpret data within the context of a patient's clinical findings
`and are rapidly adopting exome and genome wide sequencing, where access to curated knowledge is critical to
`analyze the large number of variants returned.
`
`Grant Support:
`
`Active Support:
`
`
`Federal:
`
`NIH ORD
`
`Role: Co-PI
`
`Congenital disorders of glycosylation (PI: He)
`
`
`Training Program in Human Disease Genetics. 1T32MH087977 (PI: Warren)
`
`Role: Co-PI
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`06/11-05/13
`
`Effort: 0.2 calendar-years month(s)
`
`
`
`
`
`
`
`
`
`$128,000
`
`01/11-12/15
`
` Effort: 0.12 calendar-years month(s)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`08/01/13-07/31/17
`
`Effort: 0.2 calendar-year
`
`$ 2,000,000
`
`
`
`
`1 UM1 (PIs: Berg)
`
`Role: Co-investigator
`month(s)
`
`NIH/NHGRI
`
`Clinically Relevant Variants Resource (CRVR)
`
`The overarching goal of the Clinically Relevant Variants Resource (CRVR) is to generate a knowledge base of genes
`and variants for use in the clinical setting. During the first year of the project, we will establish taskforces for the
`assessment of genes and variants, and coordinate the establishment of the informatics infrastructure required to
`support the activities of the project and provide points of access to the information in CRVR. During years 2-4, we will
`convene clinical domain-specific working groups to carry out assessment activities, guided by of members of the
`gene assessment and variant assessment taskforces. Ethical, legal, and social implications (ELSI) will be addressed
`by providing contextual assessments and exploring the positions of various stakeholders with regard to the education
`and reporting process for the information generated. Finally, recognizing that integration of genomic information with
`electronic health records (EHRs) is critical to the future of clinical genomics, we will initiate pilot studies in years 3-4 to
`ensure interoperability between the CRVR and EHRs.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`08/01/13 – 07/31/16
`
`Effort: 0.2 calendar-year month(s)
`
`
`
`$1,653,965
`
` 1
`
` U41 HG006834-01 (PIs: Rehm/Martin/Nussbaum)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Role: Co-Investigator
`
`NIH/NHGRI
`
`Development and Curation of a Universal Human Genomic Variant Database
`
`Hundreds of thousands of disease-causing variants have been identified in patients with disease, yet only a small
`fraction of that data, and the interpretation of it, is accessible to researchers and clinicians. This project will serve to
`collect and organize genomic data from many sources into a free and publically accessible environment and enable
`expert curation of that data for use in improving healthcare and biomedical research.
`
`
`GeneDX 1003, pg. 7
`
`

`

`Madhuri R. Hegde, Ph.D.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Page 8
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`07/01/12-06/30/15
`
`Effort: 0.15 calendar-year month(s)
`
`
`
`
`
`$390,000
`
`01/01/13-01/01-14
`
`Effort: 0.15 calendar-year month(s)
`
`
`
`
`
`
`
`$88,000
`
`02/12- 03/13
`
`$47,000
`
`Effort: 0.1 calendar-years month(s)
`
`Private Foundation Funded
`
`MDA
`
`Role: PI
`
`Identification of new genes for Congenital Muscular Dystrophy
`
`
`MDA
`
`Role: PI
`
`Newborn screening for Duchenne Muscular Dystrophy
`
`
`Jain Foundation
`
`Role: PI
`
`Monocyte assay for Dysferlinopathies
`
`
`Submitted
`
`1U01HG007773-01 (PIs: Hegde)
`
`Role: PI
`
`NIH/NHGRI
`
`Medical Exome: From Concept to Implementation
`
`Over the past few year’s tremendous technological advances have pushed massively parallel sequencing based
`technology from the research to the clinical realm and have enabled simultaneous testing of unprecedented numbers
`of genes. Along with this technical advancement, massive paradigm shifts have taken place and the field is moving
`away from the traditional one gene-one disorder concept. Many genes have been shown to be related to one disorder
`or one gene can cause many disorders. Gene panels, already in place in many diagnostic laboratories, are based on
`this concept and are derived from evidence- based review of the literature. Their main disadvantage is their static
`nature that cannot keep up with the rapid expansion of knowledge. Exome/Genome sequencing (ES/GS) is now
`feasible and beginning to be widely implemented in diagnostic laboratories despite limitations including incomplete
`coverage of medically significant genes In addition, interrogating all genes is associated with significant challenges
`as to date <25% have been established to be associated with disease. In spite of this in many cases where a clinical
`phenotype is not clear exome or genome sequencing has proven to be useful. To narrow the large number of
`sequence variants obtained from ES/GS, in depth and up-to date curation of gene-disease associations is of critical
`importance but not available at a systematic level. We propose to develop a “medical exome” by developing an
`algorithm for continuous curation of genes and create a technically complete exome, which covers all regions of the
`known disease associated genes. Both resources will be made available to the clinical genetics community in order
`to catalyze standardization of clinical testing.
`
`
`
`
`
`
`Previous support:
`
`NINIDS RC1
`Role: PI
`
`Comprehensive methods for Neuromuscular disorders
`
`
`Jain Foundation
`
`
`
`
`
`
`
`01/01/14-02/28/17
`
`Effort: 0.3 calendar-year month(s)
`
`
`
`
`
`$ 4,000,000
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`09/09-09/12
`$1,000,000
`
`Effort: 0.4 calendar-years month(s)
`
`
`
`
`
`08/11- 01/12
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`GeneDX 1003, pg. 8
`
`

`

`Madhuri R. Hegde, Ph.D.
`
`
`
` Page 9
`
`Role :PI
`
`Copy number variation in the Dysferlin Gene
`
`
`P.I., Muscular Dystrophy Association “ Infrastructure Grant for translation new technologies to
`NMD testing”
`
`
`
`
`
`
`
`
`
` 2/00-12/10
`U01 DK56956 (Chapman) Co-investigator NIH/NIDDK
`The Early Collaborative Clinical Studies in PKD: The Consortium for Radiologic Imaging Studies of PKD (CRISP)
`Extended Cohort
`
`
`
`
`P.I., NIH ORD- CETT Program” X-linked Mental Retardation” 02/09-06/10
`
`
`
`
`
`
`P.I., Muscular Dystrophy Association
`“Microarray based Mutation detection in genes associated with Neuromuscular disorders”
`
`
`
`
`P.I., Parent Project Muscular Dystrophy
`“Use of dried blood spots to detect mutation in Duchenne Muscular
`Dystrophy”, Sub Contract: Emory Genetics Laboratory
`
` MM-1097-09/09 Center for Disease Control and Prevention (CDC)
`Association of American Medical Colleges (AAMC), Co-investigator
` Qualitative and quantitative study to determine the barriers to the early diagnosis of Duchenne and Becker Muscular
`Dystrophy (DBMD) (Andrew Faucett)
`
` 01/02-01/03
`
` P.I., Vision of Children foundation
`“Genetic analysis of X-linked Ocular Albinism” P.I., Muscular Dystrophy Association
`01/02-01/04
`“Studies in detection of point mutations in the dystrophin gene”
`
`
` P.I., Baylor Research to Clinical transition Fund (HNPCC)
` “Analysis of HNPCC carrier identification in an ethnically diverse population”
`
`Co-investigator., “Gene Identification for Idiopathic Hyperphosphatasia”
`School of Medicine, University of Auckland, Auckland, New Zealand (Prof. Tim Cundy)
`
`
`Equipment Grant:
`
`ACTSI Proof of Principle Fund
`
`This fund is to support the rapid evaluation and translation of high-impact emerging technologies (Translational
`Technologies & Resources (TTR) program). These funds, along with support from the Georgia Research Alliance
`(GRA), are used to invest in new, promising technologies that are aligned with the ACTSI strategic goals.
`
`RainDance Technologies RDT 1000 instrument for multiplex PCR to enhance targeted sequencing capabilities in the
`Emory Genetics Laboratory.
`
`March Of Dimes (Georgia Branch)
`
`Qiagen Automated DNA extraction System
`
`
`
`Formal Teaching:
`
`Medical Student Teaching:
`
`
`Medi 545: Human and Molecular Genetics
`Lecturer and Small Group Facilitator
`Emory University School of Medicine
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`$20,000
`
`Effort: 0.1 calendar-years month(s)
`
`09/09 – 09/11
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` 09/08 – 09/09
`
` 01/09 – 06/09
`
` 01/09-12/09
`
` 03-02-02/04
`
` 09/99-01/01
`
`
`
`
`
`2010
`
`2007
`
`2006 –
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`GeneDX 1003, pg. 9
`
`

`

`Madhuri R. Hegde, Ph.D.
`
`
`
` Page 10
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2010-
`
`2002 – 2006
`
` 2004-2006
`
`
`
`
`
`
`
`
`
`
`
`
`
`November 2011
`
`2013
`
`2012
`
`2012
`
`2012
`
`2011-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Medical Residents Lecture Series (Pediatrics)
`
`
`Graduate Program:
`
`Clinical Pathology Conference for Residents and Fellows
`Lecturer, Department of Genetics, Baylor College of Medicine
`
`
`
`
`
`
`Molecular Genetics Technology Program
`Lecturer, The University of Texas M.D. Anderson Cancer Center
`School of Health Sciences
`
`Undergraduate Teaching:
`
`Undergraduate Genetics Class
`Georgia Institute of Technology
`
`
`Other:
`
`
`ACMG Review course
`
`
`
`
`
`Course Director and Faculty
`American College of Medical Genetics, Next Generation sequencing
`
`
`
`
`
`
`
`
`Course Faculty
`International Society of Prenatal Diagnosis, Next Generation sequencing
`
`
`
`
`
`Course Director and Faculty
`Cambridge Health Institute (CHI), Next Generation sequencing
`
`Composite letter writer, Emory College
`
`Microbiology Laboratory, Lecturer
`S.N.D.T Women’s University, Bombay, India
`
`
`Supervisory Teaching:
`
`Post-doctoral Fellows Directly Supervised:
`
`
`
`
`
`
`Alice Tanner
`Medical Genetics Fellow, ABMG Training program
`
`Melanie Jones
`Medical Genetics Fellow, ABMG Training program
`Research
`
`
`
`
`
`Eli Williams
`Medical Genetics Fellow, ABMG Training program
`
`Arunkanth Ankala
`Research
`
`
`
`
`Heather Mason-Suares
`Medical Genetics Fellow, ABMG Training program
`
`
`
`
`Vanessa Horner
`Medical Genetic Fellow, ABMG Training program
`
`Past:
`
` 1992 – 1993
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2011-
`
`2010-
`
`2012-
`
` 2010-
`
`2012-
`
`2012-
`
`
`
`
`
`
`
`GeneDX 1003, pg. 10
`
`

`

`Madhuri R. Hegde, Ph.D.
`
`
`
` Page 11
`
`2009-2012
`
`2009-2011
`
`
`
`
`
`
`
`
`
`2009-2010
`
`2009-2011
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2005-2006
`
`
`Alexander Valencia Ph.D.
`Medical Genetics Fellow, ABMG Training program
`
`Victor Zhang, PhD.
`Medical Genetics Fellow, ABMG Training program, Emory University
`
`Cindy McClomskey M. D
`Molecular Pathology Fellow, Molecular Pathology, Training program)
`
`Hussian Askree M.D., Ph.D.
`Medical Genetics Fellow, ABMG Training program, Emory University
`
`Kavita Gokhale Ph.D. 2008-2010
`(Research)
`
`
`Marwan Tayeh, PhD. 2007-2010
`Medical Genetics Fellow, ABMG Training program, Emory University
`
`David Okou, PhD. 2009
`Medical Genetics Fellow, ABMG Training program, Emory University
`
`Christine Schmotzer M. D 2009
`Molecular Pathology Fellow, Molecular Pathology, Training program
`
`Bipin Kulkarni, PhD 2007-2008
`(Research)
`
`Dmitriy Niyazov, M.D. 2006-2008
` (Medical Genetics Fellow, ABMG Training program)
`
`Arshad Ahsanuddin M.D. 2007
`Molecular Pathology Fellow, Molecular Pathology, Training program
`
`Justin Cole 2008
`Molecular Pathology Fellow, Molecular Pathology, Training program
`
`
`
`Monica Basehore
`
`
`
`Molecular Genetics Technology Program, M.D. Anderson Cancer Center
`
`Joanne Tran 2004
`Molecular Technology Internship
`Baylor College of Medicine
`
`Denise Juroske 2004
`Molecu